ACADIA Pharmaceuticals Inc

NASDAQ:ACADUnited States

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Contact Information

Headquarters

12830 El Camino Real, Suite 400SAN DIEGO, CA, United States 92130

Phone

858-558-2871

Fax

858-558-2872

Executives

Independent Chairman of the Board

Stephen Biggar

Chief Executive Officer, Director

Stephen Davis

Chief Financial Officer, Executive Vice President

Mark Schneyer

Chief Operating Officer, Executive Vice President, Head of Commercial

Brendan Teehan

Executive Vice President and Head of Research and Development

Elizabeth Thompson